Home  »  論文一覧   »   Anti-HER2 cancer-specific mAb, H2Mab-250-hG1, possesses higher complement-dependent cytotoxicity than trastuzumab

Anti-HER2 cancer-specific mAb, H2Mab-250-hG1, possesses higher complement-dependent cytotoxicity than trastuzumab

2025年3月4日